The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

90Y Bremsstrahlung Imaging for Absorbed-Dose Assessment in High-Dose Radioimmunotherapy.

På svenska

Author

Summary, in English

This feasibility study demonstrates (90)Y quantitative bremsstrahlung imaging of patients undergoing high-dose myeloablative (90)Y-ibritumomab treatment. METHODS: The study includes pretherapy (111)In SPECT/CT and planar whole-body (WB) imaging at 7 d and therapy (90)Y SPECT/CT at 6 d and (90)Y WB imaging at 1 d. Time-activity curves and organ-absorbed doses derived from (90)Y SPECT images were compared with pretherapy (111)In estimates. Organ activities derived from (90)Y WB images at the first day were compared with corresponding pretherapy estimates. RESULTS: Pretherapy (111)In images from 3 patients were similar to the (90)Y images. Differences between absorbed-dose estimates from pretherapy (111)In and (90)Y therapy were within 25%, except for the lungs. Corresponding activity differences derived from WB images were within 25%. Differences were ascribed to incomplete compensation methods and real differences in pharmacokinetics between pretherapy and therapy. CONCLUSION: Quantitative bremsstrahlung imaging to estimate organ activities and absorbed doses is feasible.

Publishing year

2010

Language

English

Pages

1974-1978

Publication/Series

Journal of Nuclear Medicine

Volume

51

Issue

12

Document type

Journal article

Publisher

Society of Nuclear Medicine

Topic

  • Radiology, Nuclear Medicine and Medical Imaging

Keywords

  • quantification
  • activity
  • radioimmunotherapy
  • imaging
  • yttrium
  • bremsstrahlung

Status

Published

ISBN/ISSN/Other

  • ISSN: 0161-5505